The aim of this study was to develop a green method to fabricate a novel CS modified N-(4-hydroxyphenyl)- methacrylamide conjugate (CSNHMA) and to evaluate its biomedical potential. CSNHMA has been prepared by a simple method via aza Michael addition reaction between CS and N- (4-hydroxyphenyl)-methacrylamide (NHMA) in ethanol. Its structural and morphological properties were characterized by various analysis techniques. The obtained results confirmed that a highly porous network structure of CSNHMA was successfully synthesized via aza Michael addition reaction. Consequently, it was analyzed as a drug and gene carrier. CSNHMA/pGL3 showed an enhanced buffering capacity due to the presence of NHMA moiety leading to higher transfection efficiency in all cancer cells (A549, HeLa and HepG2) as compared to native CS and Lipofectamine®. Therefore, these findings clearly support the possibility of using CSNHMA as a good transfection agent. For in vitro drug release study, we prepared CSNHMA nanoparticles (NPs) and curcumin loaded CSNHMA NPs of size <230 nm respectively via the non-toxic ionic gelation route and the encapsulation efficiency of drug was found to be 77.03%. In vitro drug release studies demonstrated a faster and sustained release of curcumin loaded CSNHMA NPs at pH 5.0 compared to physiological pH.

本研究的目的是开发一种绿色方法来制备新型 CS 改性 N-(4-羟基苯基)-甲基丙烯酰胺共轭物 (CSNHMA) 并评估其生物医学潜力。CSNHMA是通过CS与N-(4-羟基苯基)-甲基丙烯酰胺(NHMA)在乙醇中发生氮杂迈克尔加成反应的简单方法制备的。其结构和形态特性通过各种分析技术进行了表征。所得结果证实，通过氮杂迈克尔加成反应成功合成了高度多孔的CSNHMA网络结构。因此，它被分析为药物和基因载体。与天然 CS 和 Lipofectamine® 相比，由于 NHMA 部分的存在，CSNHMA/pGL3 显示出增强的缓冲能力，导致在所有癌细胞（A549、HeLa 和 HepG2）中的转染效率更高。所以，这些发现清楚地支持了使用 CSNHMA 作为良好转染剂的可能性。对于体外药物释放研究，我们分别通过无毒离子凝胶途径制备了尺寸<230 nm的CSNHMA纳米颗粒（NPs）和载有姜黄素的CSNHMA NPs，发现药物的包封率为77.03%。体外药物释放研究表明，与生理 pH 值相比，负载姜黄素的 CSNHMA NPs 在 pH 5.0 时更快且持续释放。